Please login to the form below

Not currently logged in

Gilead sales rise by 13%, buoyed by anti-COVID-19 drug Veklury

The company has had a ‘very strong’ third quarter in spite of a sharp decline in its HIV portfolio due to generic competition

Gilead has reported third-quarter sales of $7.4bn, an increase of 13% compared to the same period last year, due to increased demand for its COVID-19 antiviral Veklury (remdesivir).

Without the Veklury bump, total product sales decreased by 3% to $5.4bn for the third quarter, primarily due to the loss of exclusivity of HIV combination therapies Truvada (emtricitabine/tenofovir disoproxil) and Atripla (efavirenz/emtricitabine/tenofovir) in the United States. The drop was also partially offset by a 20% increase to $2.3bn from Biktarvy (bictegravir/emtricitabine/tenofovir) and Trodelvy (sacituzumab govitecan-hziy), said Gilead.

Veklury saw sales of $1.9bn, more than double that of the second quarter of the year ($829m), as more than two million people received the drug or generic remdesivir.

“This was a very strong third quarter with continued positive momentum for both our commercial performance and our pipeline progress,” said Daniel O’Day, chairman and CEO. “Veklury is making a significant impact as the COVID-19 pandemic continues to evolve. The dynamics of the HIV treatment market further improved and this contributed to record Biktarvy revenue.”

O’Day also focused on the company’s oncology drugs and said: “Our marketed portfolio continues to expand with four new country approvals for Trodelvy for metastatic triple-negative breast cancer, the approval of Tecartus in relapsed or refractory acute lymphoblastic leukaemia and two new trial starts for magrolimab in solid tumours.”

Its cell therapy products were a big success for Gilead, with sales increasing by 51% to $222m in the third quarter. Yescarta (axicabtagene ciloleucel) reached $175m in relapsed/refractory large B-cell lymphoma and relapsed/refractory indolent follicular lymphoma in both the US and Europe.

Sales of Tecartus (brexucabtagene autoleucel) saw $47m in mantle cell lymphoma and Trodelvy hit $101m, reflecting increased use for the second-line treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer in the US.

Gilead has updated its full-year guidance and now expects total product sales of up to $26.3bn in 2021, up from $24.4bn in 2020. While total products sales excluding Veklury are expected to be down slightly at $21.5bn (compared to $21.7bn in 2020), sales of the anti-COVID antiviral are expected to reach $4.8bn based on expected hospitalisation rates.

Although Gilead’s earnings were slightly above analysts’ predictions, the company’s share price fell by 3%.

Article by
Hugh Gosling

1st November 2021

From: Sales



Subscribe to our email news alerts

Featured jobs


Add my company
11 London

We live in a hyper-connected world. This has clear benefits for the health of our communities, our businesses and our...

Latest intelligence

Environment: where does the pharmaceutical industry stand?
The communication challenge of helping he next generation to be healthier
As the pressure on the health service increases the health of the next generation is vital for everyone. How do we show positive attitudes and change behaviour while future proofing...
Are we losing sight of what the democratisation of healthcare really looks like?
We have a core responsibility as healthcare communicators to consistently drive for better inclusion, engagement and compliance. What does the ‘democratisation of healthcare’ really look like?...